67 related articles for article (PubMed ID: 8804141)
21. A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial.
Hiance A; Chevret S; Lévy V
J Clin Epidemiol; 2009 Apr; 62(4):431-437.e2. PubMed ID: 19010642
[TBL] [Abstract][Full Text] [Related]
22. A semi-parametric Bayesian approach to average bioequivalence.
Ghosh P; Rosner GL
Stat Med; 2007 Mar; 26(6):1224-36. PubMed ID: 16832840
[TBL] [Abstract][Full Text] [Related]
23. Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial.
Zohar S; Teramukai S; Zhou Y
Contemp Clin Trials; 2008 Jul; 29(4):608-16. PubMed ID: 18201945
[TBL] [Abstract][Full Text] [Related]
24. A sample-size-optimal Bayesian procedure for sequential pharmaceutical trials.
Cressie N; Biele J
Biometrics; 1994 Sep; 50(3):700-11. PubMed ID: 7981396
[TBL] [Abstract][Full Text] [Related]
25. The Bayesian interpretation of a P-value depends only weakly on statistical power in realistic situations.
Hooper R
J Clin Epidemiol; 2009 Dec; 62(12):1242-7. PubMed ID: 19398295
[TBL] [Abstract][Full Text] [Related]
26. Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo.
Pigeot I; Schäfer J; Röhmel J; Hauschke D
Stat Med; 2003 Mar; 22(6):883-99. PubMed ID: 12627407
[TBL] [Abstract][Full Text] [Related]
27. Bayesian interim analysis in clinical trials.
Zhang X; Cutter G
Contemp Clin Trials; 2008 Sep; 29(5):751-5. PubMed ID: 18589003
[TBL] [Abstract][Full Text] [Related]
28. Robust Bayesian sample size determination in clinical trials.
Brutti P; De Santis F; Gubbiotti S
Stat Med; 2008 Jun; 27(13):2290-306. PubMed ID: 18205170
[TBL] [Abstract][Full Text] [Related]
29. [Azithromycin combined with pyrimethamine in the treatment of neurotoxoplasmosis, in an AIDS patient].
Trotta M; Sterrantino G; Milo D; Dionisio D; Leoncini F
Minerva Med; 1997 Mar; 88(3):117-9. PubMed ID: 9148227
[TBL] [Abstract][Full Text] [Related]
30. Nonparametric empirical Bayes method for comparison of treatment effects with application to stress urinary incontinence data.
Liu C; Shen W; Xie J
Pharm Stat; 2008; 7(1):42-52. PubMed ID: 17311241
[TBL] [Abstract][Full Text] [Related]
31. [Pyrimethamine and sulfadoxine as a preventive treatment for Pneumocystis carinii and Toxoplasma encephalitis].
Teira R; Virosta M; Baraia-Etxaburu J; Muñoz J; Zubero Z; Cisterna R; Santamaría JM
Enferm Infecc Microbiol Clin; 1999; 17(7):347-9. PubMed ID: 10535188
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy of toxoplasmic encephalitis in AIDS patients.
Filice G; Carnevale G; Orsolini P; Soldini L; Meroni V; Comolli G; Carenzo L
J Chemother; 1989 Jul; 1(4 Suppl):949-50. PubMed ID: 16312718
[No Abstract] [Full Text] [Related]
33. Toxoplasmic encephalitis in acquired immunodeficiency syndrome.
Chaddha DS; Kalra SP; Singh AP; Gupta RM; Sanchetee PC
J Assoc Physicians India; 1999 Jul; 47(7):680-4. PubMed ID: 10778586
[TBL] [Abstract][Full Text] [Related]
34. Borrowing strength from external trials in a meta-analysis.
Higgins JP; Whitehead A
Stat Med; 1996 Dec; 15(24):2733-49. PubMed ID: 8981683
[TBL] [Abstract][Full Text] [Related]
35. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
36. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials.
Diamond GA; Kaul S
J Am Coll Cardiol; 2004 Jun; 43(11):1929-39. PubMed ID: 15172393
[TBL] [Abstract][Full Text] [Related]
37. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.
Johnson SR; Feldman BM; Pope JE; Tomlinson GA
J Rheumatol; 2009 Feb; 36(2):323-9. PubMed ID: 19040308
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.
Chirgwin K; Hafner R; Leport C; Remington J; Andersen J; Bosler EM; Roque C; Rajicic N; McAuliffe V; Morlat P; Jayaweera DT; Vilde JL; Luft BJ
Clin Infect Dis; 2002 May; 34(9):1243-50. PubMed ID: 11941551
[TBL] [Abstract][Full Text] [Related]
39. Early stopping to accept H(o) based on conditional power: approximations and comparisons.
Betensky RA
Biometrics; 1997 Sep; 53(3):794-806. PubMed ID: 9290216
[TBL] [Abstract][Full Text] [Related]
40. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
